once-weekly semaglutide in adults with alcohol use disorder GLP-1 medications: The next big

Contact your healthcare provider if you experience: Severe or persistent cramps that do not respond to self-care measures or significantly impact your quality of life and daily activities Frequent cramping occurring multiple times daily or nightly, disrupting sleep and functioning Associated symptoms including muscle weakness, numbness, tingling, or changes in sensation, which may suggest neurological involvement Swelling, redness, or warmth in the affected leg, which could indicate deep vein thrombosis or other vascular complications Severe gastrointestinal symptoms with signs of dehydration such as decreased urination, dizziness, confusion, or rapid heartbeat Cramps that began after starting semaglutide and persist despite adequate hydration and nutritional measures Seek immediate medical attention (call 911) if you develop: Chest pain, shortness of breath, or severe abdominal pain Signs of severe dehydration including inability to keep down fluids, minimal urine output, or altered mental status Symptoms suggesting acute kidney injury, such as significantly decreased urination, swelling, or confusion Your healthcare provider can perform a comprehensive evaluation including physical examination, review of your medication regimen, and laboratory testing to assess electrolyte levels, kidney function, and other relevant parameters

Furthermore, it slows down the rate of gastric emptying in the early postprandial phase

MET-097i vs Semaglutide: Ultra-Long-Acting vs Established GLP-1 Comparison Evidence-based comparison of MET-097i (ultra-long-acting once-monthly GLP-1 agonist) and semaglutide (established once-weekly/daily GLP-1 agonist) for weight loss and obesity treatment

For patients confirmed to need b12 supplementation, either approach works

Increased Risk of Hair Loss With GLP-1 Receptor Agonists: A Real-World Multicenter Cohort Study